This will help to identify the correct targeted treatment for each individual subtype of the disease. Actually, people with pancreatic cancer have a poor prognosis, with a median survival measured in just months and a five year survival rate of less than five per cent. The disease progresses “silently” within the pancreas for up to 15 to 20 years, until patients present to the clinic when they are in the later stages of the disease. The current methods of treating pancreatic cancer are not targeted or selective. In fact, according to the first author Dr Peter Bailey, “the standard of care for pancreatic cancer really hasn’t changed in the last 20 years.”
This research could help to find a way to change the clinical landscape for, not only pancreatic cancer, but all cancers by providing a very thorough analysis of the molecular pathology of specific cancers.